Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL2171746 | 0.97 | CA2 (0.32) | CA2 | |
| SCHEMBL27623481 | 0.96 | CA2 (0.35) | CA2 | |
| SCHEMBL52 | 0.96 | CA2 (0.35) | CA2 | |
| SCHEMBL20135729 | 0.93 | CA2 (0.33) | CA2 | |
| SCHEMBL3945654 | 0.93 | CA2 (0.33) | CA2 | |
| SCHEMBL11001716 | 0.93 | CA2 (0.33) | CA2 | |
| Water SCHEMBL6513542 | 0.93 | CA2 (0.33) | CA2 | |
| Hydrochloric Acid SCHEMBL8958370 | 0.93 | CA2 (0.33) | CA2 | |
| Hydrogen Peroxide SCHEMBL2051538 | 0.93 | CA2 (0.33) | CA2 | |
| SCHEMBL3945657 | 0.93 | CA2 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348031-B9 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienediones as antiprogestational agents | US GOV HEALTH & HUMAN SERV (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2348031-B1 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienediones as antiprogestational agents | US GOV HEALTH & HUMAN SERV (US) | 2015-06-17 | — | — | EP | disclosed |
| US-20140107089-A1 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-04-17 | — | — | US | disclosed |
| US-8569276-B2 | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2348030-A2 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2348031-A2 | 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2033965-A2 | 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20050143365-A1 | Structural modification of 19-norprogesterone I: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | NATIONAL INSTITUTES OF HEALTH | 2005-06-30 | — | — | US | disclosed |
| US-6900193-B1 | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1265911-A2 | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001074840-A2 | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNA 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2001-10-11 | — | — | WO | disclosed |
| US-5231013-A | Staphylococcus biosynthesis | DR. KARL THOMAE GMBH (DE) | 1993-07-27 | — | — | US | disclosed |
| EP-0342486-B1 | ANTIBIOTIC | Dr. Karl Thomae GmbH (DE) | 1992-05-06 | — | — | EP | disclosed |
| EP-0342486-A1 | Antibiotic | Dr. Karl Thomae GmbH (DE) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107089-A1 | STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS | CYP19A1, HSD17B11, CYP17A1 | CA2 4434/4885 |
| US-20050143365-A1 | Structural modification of 19-norprogesterone I: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | HSD17B11, NR5A1, CYP19A1 | CA2 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.